This multiple sclerosis treatment stock is in a handle of a long cup base. It recently raised its 2026 revenue forecast.

The trial includes 48 patients with non-active secondary progressive multiple sclerosis (na-SPMS) across the U.S. ・The efficacy of the trial will be assessed using PET imaging, MRI scans, clinical ...

Two experimental drug molecules promoted myelin repair in MS disease models, pointing toward a possible future route for ...

A new study offers clues as to why exercise can improve neurological symptoms in people with multiple sclerosis (MS).

A new study offers clues as to why exercise can improve neurological symptoms in people with multiple sclerosis (MS). The study, led by investigators from Mass General Brigham and University Medical ...

DNA damage from inflammation outpaces the cells’ ability to self-repair. The finding, in human brain cells and mice, could ...

Tiziana Life Sciences (TLSA) stock is in focus as the company posts new data from an intranasal version of lead asset ...

Summary: A neuroimmunology study uncovered the cellular mechanism decoding why exercise improves neurological symptoms in multiple sclerosis (MS). The research demonstrates that irisin, a hormone ...

Enrollment has reached 50% in an ongoing study testing whether a PET tracer can reliably measure myelin damage in people with ...

Why is MS gut health rarely discussed? Trevis Gleason explores the gut-brain connection, the International MS Microbiome Study, and why experts are hesitant to go "on the record" about this evolving ...